The Mumbai-primarily based mostly completely energetic prescribed drugs components (APIs) producer, Supriya Lifescience, is about to open its Supriya Lifescience Restricted IPO GMP on December 16. The corporate produces 38 APIs centered on totally different therapeutic segments comparable to antihistamines, ache relievers, anesthetics, nutritional vitamins, anti-asthmatic and anti-allergic medication. Supriya Lifescience merchandise had been exported to 86 nations and 1,296 purchasers in FY21. The company has API enterprise in Europe, Latin America, Asia, and North America. He’s seeking to elevate 700 crores via the IPO, which consists of a brand new challenge of 200 crore and a promote provide of ₹ 500 crore.
Supriya Lifescience Restricted IPO GMP
- Supriya Lifescience manufactures Energetic Pharmaceutical Components (APIs). It produces 38 components centered on therapeutic segments comparable to ache relievers, anesthetics, antiallergics,
- It seeks to boost 700 crores via the IPO which consists of a brand new challenge of ₹ 200 crore and a promote provide of ₹ 500
- The corporate’s IPO will open and shut on December It has a worth vary of 265-274 per share.
- Particular person traders can bid on a minimal of 54 shares with a worth of 14,796 per
Objects of the Difficulty
- Financing of the Firm’s funding expenditure necessities;
- Compensation and/or prepayment, in complete or partly, of sure loans utilized by the Firm and
- Normal business functions
Supriya Lifescience Restricted IPO Particulars
| Objects of the problem |
|
| Difficulty Dimension |
|
| Face worth | Rs.2.00 Per Fairness Share |
| Difficulty Value | Rs. 265 – Rs.274 |
| Bid Lot | 54 shares |
| Itemizing at | BSE, NSE |
| Difficulty Opens: | 16thDec, 2022 – 20th Dec, 2022 |
| QIB | 75% of Web Difficulty Provide |
| Retail | 10% of Web Difficulty Provide |
| NIB | 15% of Web Difficulty Provide |
Necessary Dates Related With The IPO
| Value Band | ₹265 To ₹274 |
| IPO Open Date | December 16 |
| IPO Shut Date | December 20 |
| Allotment Date | December 23 |
| Initiation Of Refunds | December 24 |
| Credit score Of Shares To Demat Account | December 27 |
| IPO Itemizing Date | December 28 |
| Minimal Lot | 54 |
The web proceeds of the brand new challenge will probably be used for capital expenditures, debt reimbursement, and common enterprise functions.
Supriya Lifescience IPO Provisional Timetable
The Supriya Lifescience IPO open date is Dec 16, 2022, and the close to date is Dec 20, 2022. The issue may additionally moreover record on Dec 28, 2022.
| IPO Open Date | Dec 16, 2022 |
| IPO Shut Date | Dec 20, 2022 |
| Foundation of Allotment Date | Dec 23, 2022 |
| Initiation of Refunds | Dec 24, 2022 |
| Credit score of Shares to Demat Account | Dec 27, 2022 |
| IPO Itemizing Date | Dec 28, 2022 |
Supriya Lifescience IPO Date And Value Band
| IPO Open: | 16 December 2022 |
| IPO Shut: | 20 December 2021 |
| IPO Dimension: | Approx ₹700 Crores |
| Contemporary Difficulty: | Approx ₹200 Crores |
| Provide for Sale: | Approx ₹500 Crores |
| Face Worth: | ₹2 Per Fairness Share |
| Value Band: | ₹265 to ₹274 Per Share |
| Itemizing on: | BSE & NSE |
| Retail Quota: | 10% |
| QIB Quota: | 75% |
| NII Quota: | 15% |
| Low cost: | ₹- for Retail Buyers |
Firm’s Deal with
Supriya Lifescience Restricted
207/208, Udyog Bhavan, Sonawala Street,
Goregaon–East, Mumbai – 400063,
Maharashtra, India
Tel: +91-22-40332727
Contact Particular person: Shweta Shivdhari Singh
Firm Secretary and Compliance Officer
Tel: +91-22-40332727
E-mail: [email protected]
Web site: www.supriyalifescience.com
Company Identification Quantity: U51900MH2008PLC180452OUR
Supriya Lifescience Firm Monetary Report (Cr)
| Yr | Income | Expense | P&L |
| 2021 | ₹25,993.50 | ₹23,694.00 | ₹1,520.73 |
| 2020 | ₹21,762.53 | ₹21,377.81 | ₹230.24 |
| 2019 | ₹21,591.22 | ₹21,037.06 | ₹851.33 |
Supriya Lifescience Restricted IPO Threat Elements
- The corporate generates a good portion of its income from just a few gamers, so a lack of prospects can have a major affect on the corporate’s income.
- The corporate operates in a extremely regulated business and should adhere to the security and manufacturing laws of varied companies, so any deficiency in manufacturing requirements might preclude their
Supriya Lifescience Restricted IPO Outlook
Supriya Lifesciences Restricted is the biggest exporter of chlorpheniramine maleate, Ketamine hydrochloride, and India salbutamol sulfate, supplies their product in India and International Pharma Firm, about 70% of revenues come from the export market wherein they supply
Supriya’s facility is licensed by the entire world’s high pharmaceutical companies and has sturdy RandD functionality and often enters area of interest merchandise.
The corporate has proven sturdy monetary efficiency over the previous three years and this pattern is anticipated to proceed as a consequence of China’s plus one coverage and the federal government’s initiative to grow to be self-sufficient within the API house.
On the highest worth bracket of 274,274, the corporate will commerce at a P / E of 17.81x after the issuance of FY21E, which is consistent with different API corporations, so we advocate that you simply SIGN UP for this Supriya Lifescience Restricted IPO GMP.